AmerisourceBergen Corporation (ABC)
(Delayed Data from NYSE)
$79.14 USD
+2.08 (2.70%)
Updated May 3, 2019 04:01 PM ET
After-Market: $79.11 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$79.14 USD
+2.08 (2.70%)
Updated May 3, 2019 04:01 PM ET
After-Market: $79.11 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Here's Why Investors Should Retain LabCorp (LH) Stock for Now
by Zacks Equity Research
Investors are optimistic about LabCorp (LH) on strategic partnerships and upbeat guidance.
Shockwave Medical (SWAV) Launches IVL Catheter in Select Markets
by Zacks Equity Research
Shockwave Medical's (SWAV) latest commercial availability and the patient enrollment in its study are expected to serve a wider patient pool.
Abbott's (ABT) New Pact to Advance Clinical Trials Diversity
by Zacks Equity Research
Abbott's (ABT) latest additions to Diversity in Clinical Trials effort expand upon the alliances, awards and the emphasis on diverse participation in its own clinical trials.
Here's Why You Should Retain Veeva Systems (VEEV) Stock Now
by Zacks Equity Research
Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock.
Here's Why You Should Retain Veradigm (MDRX) Stock for Now
by Zacks Equity Research
Veradigm (MDRX) continues to hold on to investors' interests owing to its strategic alliances.
National Vision (EYE) Q1 Earnings Top Estimates, Margins Down
by Zacks Equity Research
National Vision's (EYE) Q1 net revenues are positively impacted by the timing of unearned revenue.
Here's Why You Should Retain Patterson Companies (PDCO) Stock Now
by Zacks Equity Research
Investors remain optimistic about Patterson Companies (PDCO) on the back of its broad product line.
Why You Should Buy The Cooper Companies (COO) Stock Now
by Zacks Equity Research
The Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to drive the top line further.
NextGen (NXGN) Behavioral Health Suite to Focus on Mental Health
by Zacks Equity Research
NextGen's (NXGN) Behavioral Health Suite is expected to offer better access to care and improve patient outcomes.
Revvity's (PKI) Q1 Earnings Top, '23 View Below Expectations
by Zacks Equity Research
Revvity's (PKI) first-quarter results reflect the impact of transition following divestment of AES business. While earnings outpace estimates, sales miss the same.
Fresenius Medical (FMS) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Fresenius Medical's (FMS) first-quarter revenues benefit from strong performances across all segments, especially the North America and Asia-Pacific regions. However, rising costs hurt margins.
Masimo (MASI) Q1 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Masimo's (MASI) robust product shipments and continued strength in its healthcare business drive its Q1 sales.
DaVita (DVA) Tops Q1 Earnings Estimates, Ups FY23 EPS View
by Zacks Equity Research
DaVita's (DVA) robust revenues in both segments drive its first-quarter performance.
Shockwave Medical (SWAV) Q1 Earnings Top, Revenues Surge Y/Y
by Zacks Equity Research
Shockwave Medical's (SWAV) first-quarter results reflect robust revenue growth and gross margin expansion on the back of strong demand and new launches.
McKesson (MCK) Q4 Earnings Beat Estimates, U.S. Sales Strong
by Zacks Equity Research
McKesson's (MCK) fiscal fourth-quarter 2023 results benefit from growth in the United States. Divestment hurt the International segment.
Avanos (AVNS) Q1 Earnings and Revenues Fall Shy of Estimates
by Zacks Equity Research
Despite strength in Avanos' (AVNS) Chronic Care segment, its overall first-quarter results reflect soft performances.
AMN Healthcare (AMN) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
AMN Healthcare's (AMN) dismal results in all its segments led to a soft overall Q1 performance.
Inogen (INGN) Q1 Earnings Beat Estimates, Revenues Lag
by Zacks Equity Research
Despite higher domestic business-to-business sales and rental revenues, Inogen's (INGN) overall first-quarter results reflect soft performances.
Should Value Investors Buy AmerisourceBergen (ABC) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
3 Reasons Growth Investors Will Love AmerisourceBergen (ABC)
by Zacks Equity Research
AmerisourceBergen (ABC) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Is AmerisourceBergen (ABC) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how AmerisourceBergen (ABC) and Align Technology (ALGN) have performed compared to their sector so far this year.
AmerisourceBergen (ABC) Beats on Q2 Earnings, Ups '23 EPS View
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal second-quarter 2023 results benefit from segmental growth. Inflation and unfavorable currency rates hurt operating margin.
AmerisourceBergen (ABC) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
AmerisourceBergen (ABC) delivered earnings and revenue surprises of 6.38% and 4.36%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
AmerisourceBergen (ABC) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal 2023 second-quarter results are likely to reflect solid performance in the U.S. Healthcare Solutions segment.
AmerisourceBergen's (ABC) New JV to Boost Oncology Care
by Zacks Equity Research
AmerisourceBergen's (ABC) new JV is expected to provide the independent community oncology network with additional resources and expertise to grow the platform and improve patient outcomes.